Hoth Therapeutics Celebrates Unprecedented Success in Cancer Drug Trial with HT-001

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a prominent biopharmaceutical entity, has recently shared promising interim results from its Phase 2a clinical trial of HT-001, a groundbreaking treatment targeting skin toxicities associated with Epidermal Growth Factor Receptor Inhibitors (EGFRi) in cancer patients. These findings mark a significant advancement in patient care, showcasing HT-001's vital role in ensuring effective cancer treatment without compromising quality of life.

In the open-label trial segment known as CLEER-001, incredible results emerged: all patients achieved the primary endpoint of an Acneiform Rash Investigator Global Assessment (ARIGA) score of less than or equal to one within six weeks. This performance not only demonstrates a significant improvement in skin toxicity but also highlights the treatment's efficacy in reducing discomfort levels often associated with cancer therapies. Additionally, 66% of participants reported decreased pain and itching, contributing to an enhanced overall quality of life during their treatment journey.

One of the most significant revelations from this trial is that every patient maintained their full dosage of EGFRi, a notable contrast to past experiences where patients frequently faced dosage reductions or halts due to skin-related side effects. This ability to sustain treatment levels while alleviating adverse effects from skin toxicities welcomes a new paradigm in cancer care, emphasizing the importance of patient quality of life alongside treatment efficacy.

The trial employs a novel scoring assessment, the ARIGA scale, developed in collaboration with leading experts in onco-dermatology. This advanced scale ensures precise measurement and evaluation of skin toxicity improvements, allowing for a comprehensive understanding of HT-001's impact. Robb Knie, CEO of Hoth Therapeutics, expressed enthusiasm about the trial's results, stating, "These results are a significant milestone, underscoring HT-001's potential to transform patient care by mitigating debilitating skin toxicities while maintaining critical cancer treatments. Our data highlight HT-001's strong safety profile and the potential for it to set a new standard of care in this underserved area."

No treatment-related adverse effects have been reported thus far, further establishing HT-001's impressive safety profile. Knie added, "These interim findings align with a recent case report of rapid resolution of EGFRi-induced skin conditions using HT-001. As the study progresses, we anticipate further validating these results and are excited about the potential impact HT-001 could have on patient outcomes."

Hoth Therapeutics is dedicated to pioneering progressive treatments with the ultimate goal of improving patient lives. The completion of further trials and continued patient enrollment will provide more in-depth insights into the effectiveness of HT-001.

About Hoth Therapeutics, Inc.

Hoth Therapeutics focuses on delivering innovative and impactful medical therapies to enhance patient well-being. The company works alongside a skilled team of scientists, clinicians, and industry leaders to explore treatments with significant potential for breakthrough advancements. For more information about Hoth Therapeutics and their commitment to transformative healthcare solutions, visit Hoth Therapeutics.

Forward-Looking Statements

This press release contains forward-looking statements regarding Hoth's expectations, which may involve risks and uncertainties. These include the timelines for regulatory submissions, the ability to secure approval for product candidates, and various other factors affecting business operations. Hoth cautions against undue reliance on these forward-looking statements, as actual outcomes may deviate significantly due to a variety of issues and market conditions.